

FAPESP France Week 2025

CRCT
Centre de Recherches en Cancérologie Toulouse
ONCOPOLE

Cancer Research Center of Toulouse (CRCT)

Dr. Pierre Cordelier, Prof. Elizabeth Moyal, Dr. Frédéric Lopez, M. Sébastien Guibert

Université de Toulouse
Inserm
cnrs

TOULOUSE

At the heart of the Oncopole, the healthcare campus of the future

FAPESP France Week 2025

Oncopole CLAUDIUS REGAUD

INSTITUT UNIVERSITAIRE DU CANCER DE TOULOUSE Oncopole



Industrie: Pierre Fabre, Evotec campus Curie, Cyclopharma

Services: hotels, restaurants, banques, ...

Caritatifs: La Ligue 31, Fondation Toulouse Cancer Santé

Hospital: IUCT-O

Unités de recherches: CNRS, RESTORE, CREFRE, Centre Pierre Potier

CRCT


An architecture designed for translational research




Who are we ?

FAPESP France Week 2025


432 team members, including 178 researchers, 126 engineers, and 125 students




- Inserm, CNRS, OCR
- UT Assist. Prof/Prof
- UT/IUCT Assist. Prof/Prof-PH & IUCT PH
- Post-docs



- Permanent
- Contract



- PhD
- Masters'



28 different nationalities

What do we do ?

RNA

Signalling

Microenvironment

Clin. pharmacol.

S. Millevoi
RNA-binding proteins and genotoxic stress

S. Pyronnet / F. Meggetto,
RNA biology in hematological tumors

G. Favre / O. Sordet
Cell signalling, oncogenesis and therapeutics

P. Cordelier
Therapeutic innovation in pancreatic cancer

J. Guillermet-Guibert
Integrated cellular signalling and class I-II-III isoforms of PI3K

L. Scipioni
Advanced microscopy for the study of chemoresistance and heterogeneity in breast cancer

C. Bousquet
Microenvironment and therapeutic resistance in pancreatic neoplasms

E. Moyal
Optimising radiotherapy: from molecular signalling pathways to clinical trials

F. Thomas / E. Chatelut
Dose individualization of anticancer drugs

Immunooncology

Tumor genetics

Oncometabolism

E. Delabesse
Impact of genetic alterations on acute leukemia development

F. Chibon
Oncogenesis of sarcomas

L. Martinet
Genomics and immunology of myeloma

M. Ayyoub / J.P. Delord
Antitumor immunity and immunotherapy

R. Kazen / S. Valitutti
Molecular dynamics of lymphocyte interactions

V. Pancaldi
Network biology for immuno-oncology

C. Laurent
New immunotherapies against lymphoma

B. Segui / N. Andrieu-Abadie
Ceramide metabolism in melanoma: from basic mechanisms to immunotherapy

M. Poirot / S. Silvente-Poirot
Cholesterol metabolism and therapeutic innovations

J.E. Sarry
Metabolism and therapeutic resistance in acute myeloid leukemia

C. Joffre / M. Ghisi
Non-genetic adaptive mechanisms and therapy resistance in AML

What do we do ?

4 main scientific themes

Oncogenic pathways

RNA & cancer

TME and metabolism

Oncoimunology

2 transversal programs

Contribution of STEM in oncology research

Therapeutic resistance

Our technological cluster

12 highly trained enginners, Dual-certified center, one keyword: **spatial biology**

Biological collections





CRB

Advanced transcriptomics



Single-cell transcriptomics



High-throughput sequencing

Phenotypic exploration



Spectral cytometer



Inverted confocal




Multiplex imaging



High content screening

Bio informatics






Experimental models



L3





Ivis spectrum

CREFRE

Main partnerships

30% of publications co-authored

>15 clinical trials originating from translational research programs

Seed **money**


joint technological initiatives (imaging, NGS…)

Comprehensive cancer center european label

“Physical constraints and oncogenesis, biomarkers, tumor-on-a-chip”

« Modeling of complex biological processes, data mining and interpretation »

Our credo


Patient samples
(relapse)
First-in-man
clinical trials
Target / biomarker validation
Mode of action-
based, translational
research in oncology
spatio-molecular data
Patients' avatars
AI-supported
basic research
Mechanism of action
Target / biomarker identification